- Home
- ACRV vs ADCT Comparison
ACRV vs ADCT Comparison
Compare ACRV & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- ADCT
- Stock Information
- Founded
- ACRV 2018
- ADCT 2011
- Country
- ACRV United States
- ADCT Switzerland
- Employees
- ACRV 61
- ADCT N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- ADCT Health Care
- Exchange
- ACRV Nasdaq
- ADCT Nasdaq
- Market Cap
- ACRV 73.5M
- ADCT 143.1M
- IPO Year
- ACRV 2022
- ADCT 2020
- Fundamental
- Price
- ACRV $2.24
- ADCT $1.49
- Analyst Decision
- ACRV Strong Buy
- ADCT Strong Buy
- Analyst Count
- ACRV 6
- ADCT 5
- Target Price
- ACRV $21.80
- ADCT $8.50
- AVG Volume (30 Days)
- ACRV 162.1K
- ADCT 344.2K
- Earning Date
- ACRV 05-13-2025
- ADCT 03-27-2025
- Dividend Yield
- ACRV N/A
- ADCT N/A
- EPS Growth
- ACRV N/A
- ADCT N/A
- EPS
- ACRV N/A
- ADCT N/A
- Revenue
- ACRV N/A
- ADCT $70,837,000.00
- Revenue This Year
- ACRV N/A
- ADCT $6.81
- Revenue Next Year
- ACRV N/A
- ADCT $11.24
- P/E Ratio
- ACRV N/A
- ADCT N/A
- Revenue Growth
- ACRV N/A
- ADCT 1.84
- 52 Week Low
- ACRV $2.14
- ADCT $1.39
- 52 Week High
- ACRV $11.90
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- ACRV 22.41
- ADCT 39.46
- Support Level
- ACRV $5.00
- ADCT $1.41
- Resistance Level
- ACRV $5.65
- ADCT $1.68
- Average True Range (ATR)
- ACRV 0.44
- ADCT 0.12
- MACD
- ACRV -0.33
- ADCT -0.03
- Stochastic Oscillator
- ACRV 2.85
- ADCT 16.00
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.